CN100344624C - 含有精氨酰胺类的医药制剂 - Google Patents

含有精氨酰胺类的医药制剂 Download PDF

Info

Publication number
CN100344624C
CN100344624C CNB2004800076128A CN200480007612A CN100344624C CN 100344624 C CN100344624 C CN 100344624C CN B2004800076128 A CNB2004800076128 A CN B2004800076128A CN 200480007612 A CN200480007612 A CN 200480007612A CN 100344624 C CN100344624 C CN 100344624C
Authority
CN
China
Prior art keywords
solution
pharmaceutical composition
argatroban
pharmaceutical preparation
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CNB2004800076128A
Other languages
English (en)
Chinese (zh)
Other versions
CN1761661A (zh
Inventor
尾崎和彦
平宫真奈美
吉泽胜芳
山田孝志
广川毅
菅原浩一
来栖克典
山田昇
梶原健一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33027937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100344624(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of CN1761661A publication Critical patent/CN1761661A/zh
Application granted granted Critical
Publication of CN100344624C publication Critical patent/CN100344624C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB2004800076128A 2003-03-20 2004-03-19 含有精氨酰胺类的医药制剂 Ceased CN100344624C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003077125 2003-03-20
JP077125/2003 2003-03-20

Publications (2)

Publication Number Publication Date
CN1761661A CN1761661A (zh) 2006-04-19
CN100344624C true CN100344624C (zh) 2007-10-24

Family

ID=33027937

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800076128A Ceased CN100344624C (zh) 2003-03-20 2004-03-19 含有精氨酰胺类的医药制剂

Country Status (5)

Country Link
JP (1) JP3781308B2 (enExample)
KR (1) KR101010547B1 (enExample)
CN (1) CN100344624C (enExample)
TW (1) TW200505422A (enExample)
WO (1) WO2004083201A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008696A (ja) * 2003-03-20 2006-01-12 Mitsubishi Pharma Corp アルギニンアミド類を含有する医薬製剤
CN101257890B (zh) * 2005-09-01 2012-10-31 巴克斯特国际公司 含有酸作为增溶剂的阿加曲班制剂
JP5438999B2 (ja) * 2009-03-19 2014-03-12 テルモ株式会社 アルガトロバン注射液製剤
CN102120026A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以醇作为增溶剂的21(s)阿加曲班静脉注射液
CN102228426A (zh) * 2011-06-17 2011-11-02 天津市炜杰科技有限公司 以醇作为增溶剂的21(r)阿加曲班静脉注射液
CN104098647B (zh) * 2014-06-24 2017-12-08 安徽省逸欣铭医药科技有限公司 阿加曲班类似物及其制备方法和医药用途
CN114689768A (zh) * 2020-12-31 2022-07-01 汉寿康运医药科技有限公司 一种阿加曲班一水合物中杂质含量的分离检测方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214052A (en) * 1987-07-28 1993-05-25 Mitsubishi Kasei Corporation Method for dissolving arginineamides and pharmaceutical compositions containing them
CN1109754A (zh) * 1994-02-03 1995-10-11 合成实验室公司 阿尔加特罗邦浓缩水溶液
JP2002241284A (ja) * 2001-02-16 2002-08-28 Towa Yakuhin Kk 全身投与用アルガトロバン注射液

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6431727A (en) * 1987-07-28 1989-02-02 Mitsubishi Chem Ind Dissolution of argininamide and drug composition containing argininamides
JP3530542B2 (ja) * 1992-03-18 2004-05-24 三菱化学株式会社 眼科用アルガトロバン製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214052A (en) * 1987-07-28 1993-05-25 Mitsubishi Kasei Corporation Method for dissolving arginineamides and pharmaceutical compositions containing them
CN1109754A (zh) * 1994-02-03 1995-10-11 合成实验室公司 阿尔加特罗邦浓缩水溶液
JP2002241284A (ja) * 2001-02-16 2002-08-28 Towa Yakuhin Kk 全身投与用アルガトロバン注射液

Also Published As

Publication number Publication date
JPWO2004083201A1 (ja) 2006-06-22
TWI327910B (enExample) 2010-08-01
TW200505422A (en) 2005-02-16
CN1761661A (zh) 2006-04-19
WO2004083201A1 (ja) 2004-09-30
JP3781308B2 (ja) 2006-05-31
KR20060002825A (ko) 2006-01-09
KR101010547B1 (ko) 2011-01-24

Similar Documents

Publication Publication Date Title
TWI476013B (zh) 具無抗氧化劑注射用溶液形態之含培美曲塞或其鹽的藥物配方之製備方法
CN1132632C (zh) 缓释药物组合物
CN1152718C (zh) 稳定的奥沙利铂溶液制剂及其制备方法
CN1060770C (zh) 无水结晶霉酚酸2－(4－吗啉代)乙酯(mycophenolate mofetil)及其静脉用制剂
CN1237106A (zh) 含有4,5－环氧吗啡喃衍生物的稳定的药物组合物
CN1268623C (zh) 组合物和使该组合物稳定的方法
CN1767856A (zh) 用作c型肝炎病毒蛋白酶抑制剂的药物组合物
CN1204960A (zh) 新的稳定的以扑热息痛为基础的制剂及其制备方法
CN1093901A (zh) 烟霉醇衍生物的稳定药物组合物
CN1448184A (zh) 包含非－类固醇消炎药剂的可注射医药组合物及其制备方法
CN1929847A (zh) 含有法舒地尔的制剂及改善其稳定性的方法
CN1761661A (zh) 含有精氨酰胺类的医药制剂
CN1092959C (zh) 包含噻加宾或其药学上可接受的盐的药物组合物和其制备方法
CN1703619A (zh) 测量非水液体组合物中的分析物的溶出速率的方法
CN1128955A (zh) 经皮吸收制剂
CN1481385A (zh) 制剂抗生素化合物的方法
CN1748704A (zh) 注射用水溶液制剂及其稳定化方法
CN1784237A (zh) 含有甲基维生素b12的冻干制剂及其制备方法
CN1287794C (zh) 用于软胶囊的含有长春瑞滨的口服医药组合物及治疗方法
CN1812794A (zh) 溶液药用组合物
CN1007958B (zh) 制备含双吲哚金属络合物的药用水溶液的方法
CN1927206A (zh) 氯诺昔康注射用组合物及其制备方法
CN1239946A (zh) 去铁胺制剂和多晶型物及其制备方法
CN1732913A (zh) 一种稳定性好的棓丙酯注射液及其制备方法
WO2017208847A1 (ja) 医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210811

Address after: Osaka, Japan

Patentee after: MITSUBISHI TANABE PHARMA Corp.

Address before: Osaka, Japan

Patentee before: MITSUBISHI PHARMA Corp.

TR01 Transfer of patent right
CX01 Expiry of patent term

Granted publication date: 20071024

CX01 Expiry of patent term
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20220705

Decision number of declaring invalidation: 56884

Granted publication date: 20071024

IW01 Full invalidation of patent right